真实世界研究中甲状腺疾病对临床妊娠结局的影响
该横断面研究纳入1521例在布鲁塞尔圣皮埃尔大学医院中心接受诊治并持续妊娠的孕妇,于中位13周检测甲状腺功能与甲状腺自身免疫,比较对照组与三个研究组六种不良妊娠结局。甲状腺自身免疫与新生儿重症监护病房入住独立相关(aOR 16.92),TSH作为连续变量与子痫前期相关(aOR 1.97)。
要点
- SCH2与子痫前期、SCH1与NICU入住及低出生体重呈趋势性关联,其他不良结局与甲状腺疾病无关。
核心结论
- 甲状腺自身免疫的孕妇其婴儿入住新生儿重症监护病房的风险显著更高,亚临床甲状腺功能减退症倾向于与子痫前期和低出生体重风险更高相关。
- 其他不良临床妊娠结局与甲状腺疾病无关,而与人口学和产科参数相关。
研究设计与样本
- 横断面研究,纳入1521例在布鲁塞尔圣皮埃尔大学医院中心(Centre Hospitalier Universitaire Saint-Pierre)接受诊治和随访并持续妊娠的孕妇。
- 于中位(Q1-Q3)13(11-17)周检测甲状腺功能(促甲状腺激素TSH、游离甲状腺素fT4)和甲状腺自身免疫(甲状腺过氧化物酶抗体)。
- 比较对照组(无甲状腺自身免疫且TSH<2.51 mIU/L)与三个研究组:孤立性甲状腺自身免疫(TSH<2.51 mIU/L)、SCH1(TSH 2.51-3.7 mIU/L)、SCH2(TSH>3.7 mIU/L)。
- 采用逻辑回归模型分析不同甲状腺分组及人口学/产科独立变量对六种不良临床妊娠结局的影响。
- 排除标准为妊娠前及妊娠期间接受甲状腺激素治疗、辅助妊娠和多胎妊娠。
主要发现
- 共记录子痫前期79例(5.2%)、宫内生长受限40例(2.6%)、早产79例(5.2%)、新生儿重症监护病房入住10例(0.66%)、低出生体重74例(4.9%)、巨大儿94例(6.2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Subclinical hypothyroidism (SCH) and thyroid autoimmunity (TAI) have been associated with poor clinical pregnancy outcomes. However, these outcomes also depend on a number of demographic and obstetric variables. Therefore, the aim of this study was to investigate the impact of thyroid disorders on these outcomes, after adjustment for associated demographic and obstetrical parameters. Methods: This is cross-sectional study including 1521 pregnant women who underwent work-up and follow-up in the Centre Hospitalier Universitaire (CHU) Saint-Pierre, Brussels, and had ongoing pregnancies. Thyroid function (thyrotropin [TSH], free thyroxine [fT4]) and TAI (thyroid peroxidase antibodies) was determined at median (Q1-Q3) 13 (11-17) weeks. Baseline parameters and the prevalence of poor clinical pregnancy outcomes were compared between controls (no TAI and TSH <2.51 mIU/L) and three study groups (isolated TAI [TSH <2.51 mIU/L], SCH1 [TSH 2.51-3.7 mIU/L], SCH2 [TSH >3.7 mIU/L]). The impact of the different thyroid groups and demographic/obstetric independent variables on six poor clinical pregnancy outcomes (preeclampsia, intrauterine growth restriction [IUGR], preterm birth, neonatal intensive care unit [NICU] admission, low birth weight, and macrosomia) was investigated in a logistic regression model. Treatment with thyroid hormone before and during pregnancy and assisted and multiple pregnancies were exclusion criteria. Results: In total, 79 preeclampsias (5.2%), 40 IUGRs (2.6%), 79 preterm births (5.2%), 10 admissions to NICU (0.66%), 74 low birth weights (4.9%), and 94 babies with macrosomia (6.2%) were documented. TAI was independently associated with NICU admission (adjusted odds ratio [aOR] 16.92 confidence interval [CI 3.36-85.29]; p < 0.001) and TSH, as a continuous variable in the whole range, with preeclampsia (aOR 1.97 [CI 1.18-3.31]; p = 0.010). Trends were present for an association between SCH2 and preeclampsia (aOR 16.73 [CI 1.43-196.42]; p = 0.025), and for SCH1with NICU admission and low birth weight (aOR 19.36 [CI 1.18-316.97]; p = 0.038 and 21.38 [CI 1.29-353.39]; p = 0.032, respectively). Conclusions: Pregnant women with TAI had a significantly higher risk of an admission of the baby to the NICU, and SCH tended to be associated with a higher risk of preeclampsia and low birth weight. Other poor clinical pregnancy outcomes were not associated with thyroid disorders, but with demographic and obstetric parameters.
引用
- Sitoris G, Veltri F, Kleynen P, et al. The Impact of Thyroid Disorders on Clinical Pregnancy Outcomes in a Real-World Study Setting. Thyroid. 2020. PMID: 31808375. doi:10.1089/thy.2019.0199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。